John P. Perentesis, MD, FAAP
- Director, Division of Oncology
- Institute Co-Executive Director, Cancer and Blood Diseases Institute
- Deb Kleisinger Endowed Chair
- Professor, UC Department of Pediatrics
- john.perentesis@cchmc.org
- Board Certified
About
Biography
I am a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. My laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. My laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, I serve in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity.
In 2010, I was elected by pediatric oncologists from across the country to the national COG Executive Committee. I also serve as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees.
I have been elected by my peers for inclusion in the Best Doctors in America List since 1998.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Interests
Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development
Services and Specialties
Interests
Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatric Blood and Cancer. 2015; 62:1739-1746.
Acute Toxicities of Proton Craniospinal Irradiation in Pediatric Medulloblastoma: A Pediatric Proton/Photon Consortium Registry (PPCR) Study. International Journal of Particle Therapy. 2025; 16:100747.
FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach. Radiation Oncology. 2024; 19:34.
Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. Nature Communications. 2024; 15:9189.
High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias. Blood. 2024; 144:2203.
Single-Cell Multi-Omic Analysis of KMT2A-Rearranged Pediatric Acute Leukemia Clonal Evolution. Blood. 2024; 144:66.
Evolution of Proton Radiation Therapy Brainstem Constraints on the Pediatric Proton/Photon Consortium Registry. Practical Radiation Oncology. 2024; 14:e507-e514.
Outcomes Following Radiation Therapy (RT) for Embryonal Tumor with Multilayered Rosettes (ETMR): Results from the Pediatric Proton/Photon Consortium Registry (PPCR). International Journal of Radiation: Oncology - Biology - Physics. 2024; 120:e697.
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205:1055-1066.
Navigating the Critical Translational Questions for Implementing FLASH in the Clinic. Seminars in Radiation Oncology. 2024; 34:351-364.
From the Blog
World’s 1st FLASH Proton Therapy Clinical Trial Shows Promise
John P. Perentesis, MD, FAAP10/24/2022
Cincinnati Children’s/UC Health Proton Therapy Center First in World to Test New Cancer Treatment That Takes Less Than 1 Second
John P. Perentesis, MD, FAAP11/19/2020
Tiny Particles, Big Medicine: New Proton Therapy Center Will Transform Cancer Care, Trigger a Wave of Discovery
John P. Perentesis, MD, FAAP6/29/2019
Still Jersey Money: We’ll Make Science Count for Kids with Cancer
11/7/2014
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey